Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease

NCT03720418 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped As a result of termination of development of OXB-102-01, it is no longer possible for Sio to either commence or to continue any related clinical trials.

Conditions

Parkinson Disease

Interventions

DRUG: OXB-102
OTHER: Imitation Surgical Procedure (ISP)

Sponsor

Sio Gene Therapies